Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03098394 · ClinicalTrials.gov registry record · NA

Use of a Rapid Test for Gonorrhea & Chlamydia for Women Presenting With Possible Sexually Transmitted Infections

A NA study, sponsored by University of Maryland, Baltimore.

Terminated
Registry status
NA
Development phase
64
Enrollment target

NCT03098394: Clinical Trial NA study, sponsored by University of Maryland, Baltimore.

NCT03098394 is a NA study that was terminated before completion, run by University of Maryland, Baltimore. The registered enrollment target is 64 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03098394, a NA study, was terminated before completion, sponsored by University of Maryland, Baltimore.

TERMINATED
Registry status
NA
Development phase
64 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the effect of utilizing a rapid turnaround CT/NG test on treatment of female patients in the emergency department or urgent care setting with possible STIs.

Primary Outcome

Evaluate the effect of a rapid turnaround CT/NG test compared to standard of care on antibiotic prescription for female patients with STI.

Interventions

  • DEVICE Cepheid Xpert CT/NG Rapid Turnaround Test
  • DEVICE Polymerase chain reaction (PCR)

Trial Details

FieldValue
Enrollment Target 64 participants
Start Date 2018-09-24
Est. Completion 2023-06-20
Phase NA
University of Maryland, Baltimore

560 total trials

Why NCT03098394 stopped before completion

NCT03098394 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).

The record links to 0 conditions, and to 2 interventions - of which Cepheid Xpert CT/NG Rapid Turnaround Test is the first listed.

NCT03098394 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03098394 about?

NCT03098394 is a clinical study titled "Use of a Rapid Test for Gonorrhea & Chlamydia for Women Presenting With Possible Sexually Transmitted Infections". The purpose of this study is to evaluate the effect of utilizing a rapid turnaround CT/NG test on treatment of female patients in the emergency department or urgent care setting with possible STIs.

What is the current status of trial NCT03098394?

This trial is currently terminated. It is a NA study. The enrollment target is 64 participants. The study started on 2018-09-24. Estimated completion is 2023-06-20.

What interventions are being tested in trial NCT03098394?

The interventions under investigation include: Cepheid Xpert CT/NG Rapid Turnaround Test (DEVICE), Polymerase chain reaction (PCR) (DEVICE).

Who is sponsoring clinical trial NCT03098394?

This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03098394's enrollment target sits among peer trials

64 1147th of 2000 higher than 844 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01853631 · 64 participants · Phase 1

    Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

  • NCT03739502 · 64 participants · Phase 2

    A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant

  • NCT03739814 · 64 participants · Phase 2

    Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

  • NCT03866408 · 64 participants · Early Phase 1

    Insulin Regulation of Lipolysis and Lipolysis Proteins

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03098394, the US trial registry maintained by the National Library of Medicine. NCT03098394 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.